Cyclopharm Limited
Appendix 4D - Half Year Report
For the half year ended 30 June 2024

To:	COMPANY ANNOUNCEMENTS		
Company:	Australian Securities Exchange	No of Pages:	39 incl. cover
Date:	27 August 2024		
From:	James McBrayer		
Subject:	**Appendix 4D and Half-year report**		

Please see attached the Appendix 4D and Half-year Report for Cyclopharm Limited (ASX:CYC) for the period ended 30 June 2024.

This announcement is made pursuant to Listing Rule 4.2A.3.

For all enquiries please contact:

Mr James McBrayer
Managing Director and Company Secretary
Cyclopharm Limited

Telephone (02) 9541 0411 or email: jmcbrayer@cyclopharm.com.au

Cyclopharm Limited
Appendix 4D - Half Year Report
For the half year ended 30 June 2024

1. Company details

Name of entity

CYCLOPHARM LIMITED

ABN or equivalent company reference	Half year ended ('current reporting period')	Half year ended ('previous corresponding period')
74 116 931 250	30 June 2024	30 June 2023

The information contained in this report is to be read in conjunction with Cyclopharm Limited's 2023 Annual Report and any announcements to the market by Cyclopharm Limited during the half year ended 30 June 2024 and up until the date of this Appendix 4D.

2. Results for announcement to the market

2.1 Revenues from ordinary activities	Down 19%	to	13,319,379
2.2 Loss from ordinary activities after tax attributable to members	Up 159% (higher loss)	to	(7,509,954)
2.3 Loss for the period attributable to members	Up 159% (higher loss)	to	(7,509,954)

2.4 Dividends	Amount per security	Franked amount per security
Final dividend proposed	Not applicable	Not applicable
Interim dividend	Not applicable	Not applicable

2.5 Record date for determining entitlements for the final dividend	Not applicable

2. Results for announcement to the market (continued)

2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable the figures to be understood.

During the six-month period, Cyclopharm continued to enhance its quality processes, systems and management expertise while investing in improvements to ensure Cyclopharm's systems and operations are well placed to support its strong growth prospects.

First revenues from the sale of Technegas™ in the United States were recorded in 1H2024 with 6 high-profile installations generating $0.25 million. These initial 6 locations are part of larger healthcare networks and their contracts extend to an additional 18 future installations. Also, at the time of this report, Cyclopharm has signed contracts for an additional 10 installations. These additional 10 installations are again part of larger hospital networks with contracts extending to an additional 37 subsequent installations. There are now signed sales contracts for up to 71 Technegas™ systems, with the initial installations being prioritised at higher patient volume sites.

With full reimbursement approval secured, we are seeing a step change in demand in the US, the world's largest healthcare market. The Center for Medicare and Medicaid Services (CMS), the peak healthcare funding body in the USA, in June 2024 awarded Technegas™ with a special 'Transitional Pass-Through' status at a rate that will fully reimburse the clinical use of Technegas™ over the next three years. This 'Pass-through' status gives hospitals a commercial incentive to adopt Technegas™ that complements the proven clinical and operational benefits it provides.

Revenue from Technegas™ products, generated primarily from the existing 64 established country markets during the half year remained broadly consistent in 1H2024, at $7.46 million, from $7.65 million in the prior corresponding period (pcp). This is a strong result given 1H2023 Technegas™ sales benefited from the global shortage of Computed Tomography (CT) contrast media that resulted in a temporary increase of imaging procedures to nuclear medicine.

Total revenue for the six months period was $13.32 million, down 19% from $16.49 million in pcp. This was primarily due to the timing of revenue from Cyclopharm's complementary third-party income stream that includes large capital equipment projects, which fell to $4.81 million in 1H2024 from $7.27 million in pcp.

The distribution of third-party products continues to deliver a meaningful additional revenue contribution for the company. This revenue is driven by a mix of radiopharmaceuticals, nuclear medicine related capital equipment projects (which is non-recurring so income timing can influence overall revenue) and the associated consumable and service revenues that flow from the capital equipment installed. Pleasingly, underlying recurring revenues generated from third-party product consumables increased by $0.15 million or 4%.

Third-party capital equipment revenue, awarded on a tender basis, is derived from distinct project work for other suppliers where Cyclopharm installs and commissions equipment used to manufacture products used in Molecular Imaging and Theragnostics. During the half year to 30 June 2024 this revenue was lower as the corresponding period in 2023 included income for a major project. A new capital works project scheduled to commence later this year is expected to drive a revenue rebound in this category for the full-year result.

Cyclotek NSW Pty Ltd, the molecular imaging joint venture collaboration between Cyclopharm, Cyclotek (Aust) Pty Ltd and the Australian Nuclear Science and Technical Organisation ('ANSTO') contributed $0.92 million to the Company's results, an increase of over 14% compared to $0.81 million in 1H2023.

The net loss before income tax for the company during the six-month period was $7.48 million, up from $2.66 million in 1H2023. This increase was mainly due to investments in expanding USA operations this year. In comparison, results for the pcp were also positively impacted by a third-party capital equipment and installation sale, a one-off legal recovery benefit and foreign exchange gains.

As of 30 June 2024, cash balances were $27.56 million. Cyclopharm is well funded and is in a strong financial position to accelerate the launch of Technegas™ in the US, while continuing to build our third-party distribution business and advancing initiatives in our Beyond PE strategy.

OUTLOOK

Cyclopharm expects continued strong demand across its 64 established country markets, where Technegas™ is the dominant nuclear medicine ventilation imaging agent for PE, to continue. The company delivered underlying recurring revenue growth in its third-party distribution business during the six months to 30 June 2024 and expects to continue to grow and broaden this business.

Cyclopharm expects full year results for third-party products to rebound during 2H2024 to finish the year on par with 2023 full year results.

The US approval of Technegas™ is expected to drive US clinician led studies that will accelerate Cyclopharm's Beyond PE strategy. This strategy is already well supported by multiple clinical trials into the use of Technegas™ in the diagnosis and management of Asthma, COPD, lung cancer and other respiratory interventional studies.

The company confirms its guidance of 300 Technegas™ generators in place by December 2025 and generating revenues.

Cyclopharm is confident Technegas™ Transitional Pass-Through status in the US, which allows for a full reimbursement for each procedure over the next three-year period, will allow for a rapid acceleration of sales in the US. This Pass-Through status, combined with Technegas™ superior performance in lung imaging procedures, underpins the Company's confidence in unlocking the US$90 million US market opportunity over the next 5 years, rising to a US$180 million opportunity over the next 8 years as Technegas™ is adopted for CTPA scans in the US. The Company continues to build capacity to drive this US success.

The combination of the strong foundation of Cyclopharm's existing Technegas™ and third-party sales business, the expected growth toward the US PE market and execution against the Company's 'Beyond PE' strategy to access additional and substantially bigger markets is expected to significantly increase revenues and shareholder value over time.

3. Net tangible assets

	30 June 2024	30 June 2023
Net Tangible Assets per security	$0.38	$0.31

4. Entities over which control has been gained or lost during the period

Control over entities

Name of entity (or group of entities)	Not applicable

Loss of control over entities

Name of entity (or group of entities)	Not applicable

5. Dividends

Not applicable

6. Dividend reinvestment plans

Not applicable

7. Details of associates and joint venture entities

Material investment in associates and joint ventures are as follows :

	30 June 2024	30 June 2023
Macquarie Medical Imaging Pty Ltd	20%	20%

The share of the associate's loss for the period was $nil (2023: $nil).

8. For Foreign Entities, which accounting standards were used in compiling this report

International Financial Reporting Standards (IFRS)

9. If the accounts have been audited or subject to review and are subject to dispute or qualification, details are described below

The accounts have been subject to review.

Cyclopharm Limited
Half Year Report 2024

Cyclopharm Limited and its Controlled Entities
ABN 74 116 931 250

cyclopharm

Contents

Highlights

Half Year ended 30 June		2024	2023	Change
Revenue	$	13,319,379	16,487,618	(3,168,239)
Loss before income tax and finance costs	$	(7,350,440)	(2,549,646)	(4,800,794)
Net Loss after tax	$	(7,509,954)	(2,895,275)	(4,614,679)
Loss Per Share	cents	(7.83)	(3.15)	(4.68)

First commercial sales of Technegas™ in the United States, Cyclopharm's 65th country market. Major progress by commercial team with signed sales contracts for up to 71 installations with a strong and growing sales pipeline.

Technegas™ now fully reimbursable for clinical use in the United States through the Center for Medicare and Medicaid Services (CMS) enabling broad industry take-up.

Consistent revenue from Technegas™ sales in the half year from the company's established markets in 64 countries globally.

Robust ongoing revenue from third-party recurring consumable sales up on prior corresponding period (**pcp**).

Successful completion of a $20 million Capital Raising in May 2024, followed by an over-subscribed $4 million Share Purchase Plan in June 2024 underscoring support from shareholders for the accelerated US commercial roll out program.

Cyclopharm's Beyond PE strategy to expand the use of Technegas™ validated by new and emerging clinical evidence.

Net cash at the half year of $27.56 million – positioning the company to deliver on our growth strategy.

Managing Director's Review

I am delighted to report Cyclopharm is expanding and progressing its sales pipeline for our Technegas™ technology in the US, following receipt of USFDA approval to market Technegas™ in the USA in October 2023.

During the six-month period, Cyclopharm continued to enhance its quality processes, systems and management expertise while investing in improvements to ensure Cyclopharm's systems and operations are well placed to support its strong growth prospects.

First revenues from the sale of Technegas™ in the United States were recorded in 1H2024 with 6 high-profile installations generating $0.25 million. These initial 6 locations are part of larger healthcare networks and their contracts extend to an additional 18 future installations. Also, at the time of this report, Cyclopharm has signed contracts for an additional 10 installations. These additional 10 installations are again part of larger hospital networks with contracts extending to an additional 37 subsequent installations. There are now signed sales contracts for up to 71 Technegas™ systems, with the initial installations being prioritised at higher patient volume sites.

With full reimbursement approval secured, we are seeing a step change in demand in the US, the world's largest healthcare market. The Center for Medicare and Medicaid Services (CMS), the peak healthcare funding body in the USA, in June 2024 awarded Technegas™ with a special 'Transitional Pass-Through' status at a rate that will fully reimburse the clinical use of Technegas™ over the next three years. This 'Pass-through' status gives hospitals a commercial incentive to adopt Technegas™ that complements the proven clinical and operational benefits it provides.

Revenue from Technegas™ products, generated primarily from the existing 64 established country markets during the half year remained broadly consistent in 1H2024, at $7.46 million, from $7.65 million in pcp. This is a strong result given 1H2023 Technegas™ sales benefited from the global shortage of Computed Tomography (CT) contrast media that resulted in a temporary increase of imaging procedures to nuclear medicine.

Total revenue for the six months period was $13.32 million, down 19% from $16.49 million in pcp. This was primarily due to the timing of revenue from Cyclopharm's complementary third-party income stream that includes large capital equipment projects, which fell to $4.81 million in 1H2024 from $7.27 million in pcp.

The distribution of third-party products continues to deliver a meaningful additional revenue contribution for the company. This revenue is driven by a mix of radiopharmaceuticals, nuclear medicine related capital equipment projects (which is non-recurring so income timing can influence overall revenue) and the associated consumable and service revenues that flow from the capital equipment installed. Pleasingly, underlying recurring revenues generated from third-party product consumables increased by $0.15 million or 4%.

Third-party capital equipment revenue, awarded on a tender basis, is derived from distinct project work for other suppliers where Cyclopharm installs and commissions equipment used to manufacture products used in Molecular Imaging and Theragnostics. During the half year to 30 June 2024 this revenue was lower as the corresponding period in 2023 included income for a major project. A new capital works project scheduled to commence later this year is expected to drive a revenue rebound in this category for the full-year result.

Cyclotek NSW Pty Ltd, the molecular imaging joint venture collaboration between Cyclopharm, Cyclotek (Aust) Pty Ltd and the Australian Nuclear Science and Technical Organisation ('ANSTO') contributed $0.92 million to the Company's results, an increase of over 14% compared to $0.81 million in 1H2023.

The net loss before income tax for the company during the six-month period was $7.48 million, up from $2.66 million in 1H2023. This increase was mainly due to investments in expanding USA operations this year. In comparison, results for the pcp were also positively impacted by a third-party capital equipment and installation sale, a one-off legal recovery benefit and foreign exchange gains.

As of 30 June 2024, cash balances were $27.56 million. Cyclopharm is well funded and is in a strong financial position to accelerate the launch of Technegas™ in the US, while continuing to build our third-party distribution business and advancing initiatives in our Beyond PE strategy.

Technegas™ Milestones following USFDA Approval

Cyclopharm's launch of Technegas™ in the United States was initiated following the United States Food and Drug Administration (USFDA) approval of Technegas™ announced in October 2023.

The first commercial contract for the use of Technegas™ in the US was signed in December 2023 followed by installation and sales of Technegas™ during 1H2024. First patients were imaged using Technegas™ from March 2024.

In May 2024 Cyclopharm updated shareholders that the CMS, the government authority that sets healthcare reimbursement rates in the United States, had awarded a unique identification code ("A9506") for Technegas™ effective from 1 July 2024, providing clinical sites with a more streamlined reimbursement process for Technegas™.

In June 2024 Cyclopharm was informed that in addition to the A-Code, Technegas™ had also been awarded the maximum three-year Transitional Pass-Through (TPT) reimbursement status by CMS. The awarded TPT rate is sufficient to fully reimburse users for each Technegas™ procedure and enable the company to create a sustained market position over this time.

In addition to the clinical and operational benefits that Technegas™ provides, with TPT status, sites will have financial incentive to implement Technegas™. The award of the maximum three years of full TPT reimbursement is expected to significantly accelerate the US launch of Technegas™.

USA Opportunity Pipeline

The US sales model for Technegas™ includes a one-off installation and training fee and ongoing recurring revenues from an annual technology access fee. Sales are then generated on an ongoing basis from per-patient consumables. Pleasingly, like an annuity revenue model, repeat per-patient consumable orders have already been received from all current US installed Technegas™ users.

As anticipated, the TPT reimbursement award is helping to accelerate contract discussions in the private sector and gives Cyclopharm confidence that it will meet its target of having 300 Technegas™ generators in place by December 2025.

Cyclopharm is actively engaged with individual sites and buying group networks in both the public and private sectors. At the time of this report the traction in the USA market is taking hold and substantial progress has been made. The following table illustrates the opportunity pipeline from the customer's request for a proposal to the revenue generating phase of installation and imaging.

US Technegas™ Sales Pipeline:	Initial Installation*	Additional Sites+	Total Potential Installations
Requested Proposal	298	24	322
Internal Committee	81	330	411
Contract Review	20	8	28
Contract Signed	10	55	65
Installed and Imaging	6	-	6
Total	**415**	**417**	**832**

**Initial Installation = Locations that are engaged for Technegas System installation*

+Additional Sites = Sites that are contractually linked to initial installations on a secondary installation basis because of size, customer priority or buying group affiliation

US Customer Conversion

The conversion process from a customer's expression of interest to revenue generation, on average to date, has spanned several months. While it is still early days since Transitional Pass Through was awarded, we are seeing an acceleration in potential customer's internal review processes.

With its dominant market position in 64 countries outside the US, the clinical benefits of Technegas™ are already well known within the nuclear medicine industry. Consequently, rather than a traditional product "sell", the sales process for Technegas™ is directed at assisting the engaged nuclear medicine department in navigating through their own internal approval processes.

These internal approval processes typically include Pharmacy & Therapeutic Committees, Radiation Safety Committees, Business Case analysis with finance and administration, Contract Reviews with legal, and reimbursement specialists charged with linking the Technegas™ A-Code and TPT reimbursement rate to the relevant imaging procedures associated with the use of Technegas™. As Technegas™ is classified as both a drug and device, additional process elements and engagements frequently include hospital departments associated with areas such as space planning and dedicated electrical installation to power for the Technegas™ system, as well as sourcing the argon gas required to manufacture Technegas™. The company's senior management, as well as its enhanced US management team, is currently well embedded in driving these approvals through to signed contracts and installations.

When fully penetrated, the US market for Pulmonary Embolism (PE), the application Technegas™ is currently best known for, is estimated to be a US$180 million per annum revenue opportunity for Cyclopharm. The Company built up significant levels of inventory prior to USFDA approval and continues to invest in generators and consumables to support a rapid market entry and expansion in the US to address the PE market. The US also represents a significant opportunity for Cyclopharm to expand the use of Technegas™ in the treatment and management of new and much larger indications that could benefit from diagnosis and treatment surveillance with Technegas™, such as Chronic Obstructive Pulmonary Disease (COPD), Asthma, Long COVID and lung cancer.

.

Clinically Preferred

Clinical guidelines are essential tools that standardise medical practice and ensure that patients receive evidence-based care that is proven to be effective. They serve as a reference for healthcare professionals, reducing variability in treatment and improving patient outcomes. By aligning practices with the latest research, clinical guidelines also promote efficient use of resources and enhance patient safety.

Technegas™ is recognised in both the European Association of Nuclear Medicine and the recently updated Canadian Association of Nuclear Medicine Guidelines as the preferred nuclear medicine ventilation imaging agent of choice in diagnosing PE, particularly in patients with small airways disease.

To underscore the clinical preference of Technegas™ in highly sophisticated markets globally, a multi-country survey which was taken before first sales of Technegas™ in the US and published this month in the Journal of Clinical Nuclear Medicine[1] noted that Technegas™ was the ventilation imaging agent of choice in 85% of respondents outside the USA. The survey indicates that the availability of Technegas™ is likely to be a key driver for US clinicians to transition to SPECT and V/Q SPECT, which have higher sensitivity and specificity and clinical use in indications other than diagnosing PE.

This finding further supports Cyclopharm's view that Technegas™ will displace existing nuclear medicine products as the lung ventilation imaging agent of choice across the US market and expand its use Beyond PE.

Beyond PE Research Supporting Expanded Uses for Technegas™

We are excited by the prospects of the use of Technegas™ for a broader range of applications beyond PE, including Asthma and COPD. These new applications are projected to be an additional market opportunity in excess of US$900 million, creating a potential total addressable market for Technegas™ of over US$1.1 billion over the longer term.

Cyclopharm estimates the global COPD market is approximately 30 times the size of the PE market and that over 500 million patients suffering with COPD and a similar number with Asthma, could benefit from the use of Technegas™. The diagnosis and monitoring of COPD, Asthma and other respiratory disease states, are all being considered in clinical trials.

Cyclopharm is already sponsor to 7 beyond PE trials exploring additional new applications for Technegas™, notably in the diagnosis and management of substantial respiratory indications such as Asthma, COPD, Lung transplant surgery, Lung cancer and Long Covid.

These include studies into the use of Technegas™ for diagnosis and management of the following conditions:

- Hunter Medical Research Institute (Newcastle, AU) - severe asthma and COPD
- Woolcock Institute (Sydney, AU) - mild to moderate COPD
- CHUM (Montreal, CA) - early detection of COPD in asymptomatic smokers
- Dalhousie (Halifax, CA) – assessing post-lung transplant patients
- McMaster University Firestone Institute (Hamilton, CA) – ventilation imaging in lung cancer patients
- McMaster University Firestone Institute (Hamilton, CA) - COVID-19 related lung injury

[1] Le Pennec R, et al Performance and Interpretation of Lung Scintigraphy: An Evaluation of Current Practices in Australia, Canada, France, Germany, and United States. Clin Nucl Med. 2024 Aug 1. doi: 10.1097/RLU.0000000000005396. Epub ahead of print. PMID: 39086050

- PRONOSPECT (France) - risk of Venous Thromboembolism (VTE) Recurrence in PE Patients

The recently published Hunter Medical Research Institute in Newcastle, Australia study demonstrated that using Technegas™ in patients with severe asthma:

- ✓ Helped to assess the effectiveness of the drug therapy
- ✓ Will help to ensure patients are being prescribed the correct drug
- ✓ Provides a safe, fast and cost-effective way of ensuring personalised treatments were working.

Strengthening the Team

Cyclopharm is expanding and strengthening its team to maximise the next growth phase for the company that has been unlocked through the USFDA approval to sell Technegas™ in USA, the world's largest healthcare market.

In Australia, Mr. Jason Smith was appointed to the role of Chief Financial Officer (CFO), on 26 February 2024. Jason has brought a wealth of industry experience to the company, having held several senior finance roles at Cochlear Ltd over a 15-year period. During his final 7 years at Cochlear he held the position of Director Financial Planning & Analysis - Asia Pacific, where he had global oversight and regional responsibilities. Jason's diverse finance experience, proven track record and strategic insights within the healthcare industry are already contributing to Cyclopharm's success.

In the United States the leadership team has been further enhanced with the February 2024 appointment of Dr. Tina Buehner as the Director of Clinical Affairs of Cyclomedica USA, LLC, a wholly owned subsidiary of Cyclopharm Limited.

Dr Buehner brings to the company the benefit of an extensive 25-year career and a distinguished background in the field of Nuclear Medicine and Molecular Imaging, having held leadership positions and committee chair appointments within the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Society of Nuclear Medicine Technologist Section (SNMMI-TS), and the Nuclear Medicine Technology Certification Board (NMTCB). Tina was honoured with a SNMMI-TS Fellowship in 2015 and has recently held the position of President of the SNMMI-TS.

To support the roll out of Technegas™ in the USA, the company has established a US Headquarters in Atlanta, Georgia and is onboarding new team members, including Service Engineers, Application Specialists, a Customer Success Manager and most recently a Business Development Manager.

Outlook

Cyclopharm expects continued strong demand across its 64 established country markets, where Technegas™ is the dominant nuclear medicine ventilation imaging agent for PE, to continue. The company delivered underlying recurring revenue growth in its third-party distribution business during the six months to 30 June 2024 and expects to continue to grow and broaden this business.

Cyclopharm expects full year results for third-party products to rebound during 2H2024 to finish the year on par with 2023 full year results.

The US approval of Technegas™ is expected to drive US clinician led studies that will accelerate Cyclopharm's Beyond PE strategy. This strategy is already well supported by multiple clinical trials into the use of Technegas™ in the diagnosis and management of Asthma, COPD, lung cancer and other respiratory interventional studies.

The company confirms its guidance of 300 Technegas™ generators in place by December 2025 and generating revenues.

Cyclopharm is confident Technegas™' Transitional Pass-Through status in the US, which allows for a full reimbursement for each procedure over the next three-year period, will allow for a rapid acceleration of sales in the US. This Pass-Through status, combined with Technegas™ superior performance in lung imaging procedures, underpins the Company's confidence in unlocking the US$90 million US market opportunity over the next 5 years, rising to a US$180 million opportunity over the next 8 years as Technegas™ is adopted for CTPA scans in the US. The Company continues to build capacity to drive this US success.

The combination of the strong foundation of Cyclopharm's existing Technegas™ and third-party sales business, the expected growth toward the US PE market and execution against the Company's 'Beyond PE' strategy to access additional and substantially bigger markets is expected to significantly increase revenues and shareholder value over time.

James McBrayer
Managing Director

Sydney, 27 August 2024

Directors' Report

The Directors of Cyclopharm Limited ("Cyclopharm" or "Group") submit their half yearly report together with the consolidated interim financial report for Cyclopharm and its controlled entities for the half year ended 30 June 2024.

DIRECTORS

The names of the company's directors in office throughout and since the end of the half year are set out below:

Mr D J Heaney	Non-Executive Chairman
Ms D M Angus	Non-Executive Director
Mr K M J Barrow	Non-Executive Director
Professor G G King	Non-Executive Director
Mr J W Wigglesworth	Non-Executive Director
Mr J S McBrayer	Managing Director

PRINCIPAL ACTIVITIES

During the half year, the principal continuing activities of the consolidated entity consisted of the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development, and installation and distribution of third-party products to the diagnostic imaging sector. There were no significant changes in the nature of the consolidated entity's principal activities during the half year.

OPERATING AND FINANCIAL REVIEW

Operating results for the half year

For the reporting period, the consolidated entity recorded a half year loss before tax of $7,477,906 (2023: loss before tax of $2,659,566).

Total revenue for the period of $13.32 million (2023: $16.49 million). Revenue from Technegas™ product lines was consistent at $7.46 million (2023: $7.65 million) while the third-party distribution business recorded a contribution of $4.81 million (2023: $7.27 million) in sales.

Income from Cyclotek NSW Pty Ltd contributed $0.92 million to total revenue (2023: $0.81 million).

Financial position

Net assets have increased from $32,259,482 as at 31 December 2023 to $47,548,989 as at 30 June 2024 principally due to a successful Capital Raising and an over-subscribed Share Purchase Plan.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

Shares issued or cancelled during the half year

(i) 93,443 ordinary shares were issued at a price of $1.83 per share on 5 April 2024 as consideration for an employee performance bonus.

(ii) 14,084,508 ordinary shares were issued at a price of $1.42 per share (11,971,832 ordinary shares issued on 30 May 2024 and 2,112,676 ordinary shares issued on 4 June 2024) in relation to a Capital Raising, and

Directors' Report
Continued

(iii) 2,818,673 ordinary shares were issued at a price of $1.42 per share on 28 June 2024 in relation to a Share Purchase Plan, and

(iv) 43,900 ordinary shares were issued at a price of $1.48 per share on 28 June 2024 as consideration for an employee performance bonus.

There were no other shares issued or cancelled during the half year.

There were no other significant changes in the state of affairs of the consolidated entity during the half year.

SIGNIFICANT EVENTS AFTER BALANCE DATE

No matters or circumstances have arisen since the end of the financial period, not otherwise dealt with in the financial report, which significantly affected or may significantly affect the operations of the economic entity, the results of those operations, or the state of affairs of the economic entity in future financial periods.

DIVIDEND

No dividend was issued for 1H2024.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 follows the Directors' Report.

This report is made and signed in accordance with a resolution of the directors made pursuant to section 306(3) of the Corporations Act 2001:

James McBrayer
Managing Director & CEO

Sydney, 27 August 2024

Nexia Australia

To the Board of Directors of Cyclopharm Limited

Auditor's Independence Declaration under section 307C of the *Corporations Act 2001*

As lead audit director for the review of the condensed consolidated financial statements of Cyclopharm Limited for the half year ended 30 June 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:

(a) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

(b) any applicable code of professional conduct in relation to the review.

Yours sincerely

Nexia Sydney Audit Pty Ltd

Stephen Fisher
Director

Sydney

Dated: 27 August 2024

Nexia Sydney Audit Pty Ltd
Level 16, 1 Market Street
Sydney NSW 2000
PO Box H195
Australia Square NSW 1215
p +61 2 9251 4600
f +61 2 9251 7138
e info@nexiasydney.com.au
w nexia.com.au

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the half year ended 30 June 2024

	Notes	Consolidated 30 June 2024 $	Consolidated 30 June 2023 $
CONTINUING OPERATIONS			
Sales revenue	3	12,274,654	14,914,983
Finance revenue		112,330	196,673
Other revenue		932,395	1,375,962
Total Revenue	4	**13,319,379**	**16,487,618**
Cost of materials and manufacturing	6(a)	(5,374,144)	(5,398,963)
Employee benefits expenses	6(b)	(7,681,701)	(5,603,371)
Advertising and promotion expenses		(616,112)	(391,815)
Depreciation and amortisation expenses	6(c)	(767,085)	(465,757)
Freight and duty expenses		(898,474)	(370,542)
Research and development expenses	6(d)	(209,469)	(3,082,837)
Administration expenses	6(e)	(5,049,407)	(3,294,327)
Other expenses		(73,425)	(429,652)
Loss before income tax and finance costs		**(7,350,440)**	**(2,549,646)**
Finance costs	6(f)	(127,466)	(109,920)
Loss before income tax		**(7,477,906)**	**(2,659,566)**
Income tax expense		(32,048)	(235,709)
Net loss for the period		**(7,509,954)**	**(2,895,275)**
Other comprehensive income after income tax			
Items that may be re-classified subsequently to profit and loss when specific conditions are met:			
Exchange differences on translating foreign controlled entities (net of tax)		(659,238)	1,243,108
Total comprehensive loss for the period		**(8,169,192)**	**(1,652,167)**
Loss per share (cents per share)	5	**cents**	**cents**
-basic loss per share from continuing operations		(7.83)	(3.15)
-basic loss per share		(7.83)	(3.15)
-diluted loss per share		(7.83)	(3.15)

The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the accompanying notes to the Consolidated Interim Financial Report.

Condensed Consolidated Statement of Financial Position

As at 30 June 2024

	Notes	Consolidated 30 June 2024 $	Consolidated 31 December 2023 $
Assets			
Current Assets			
Cash and cash equivalents		27,562,359	11,726,424
Trade and other receivables	7	8,147,302	7,895,053
Inventories	8	10,392,078	10,122,016
Current tax assets		180,223	170
Other assets		812,783	452,102
Total Current Assets		**47,094,745**	**30,195,765**
Non-current Assets			
Inventories	8	-	33,836
Property, plant and equipment		6,075,301	5,972,888
Right-of-use assets	9	4,329,318	3,213,315
Intangible assets	10	5,758,759	5,736,075
Deferred tax assets		833,724	762,310
Total Non-current Assets		**16,997,102**	**15,718,424**
Total Assets		**64,091,847**	**45,914,189**
Liabilities			
Current Liabilities			
Trade and other payables	11	8,009,600	6,941,912
Lease liabilities	12	916,317	214,465
Provisions	13	1,747,247	1,475,407
Tax liabilities		68,704	37,095
Total Current Liabilities		**10,741,869**	**8,668,879**
Non-current Liabilities			
Lease liabilities	12	4,654,826	4,012,832
Provisions	13	244,351	71,184
Deferred income	14	901,812	901,812
Total Non-current Liabilities		**5,800,989**	**4,985,828**
Total Liabilities		**16,542,858**	**13,654,707**
Net Assets		**47,548,989**	**32,259,482**
Equity			
Contributed equity	15	87,090,236	63,781,302
Employee equity benefits reserve		3,915,720	3,765,955
Foreign currency translation reserve		(1,288,541)	(629,303)
Accumulated losses		(42,168,426)	(34,658,472)
Total Equity		**47,548,989**	**32,259,482**

The Condensed Consolidated Statement of Financial Position is to be read in conjunction with the accompanying notes to the Consolidated Interim Financial Report.

Condensed Consolidated Statement of Cash Flows

For the half year ended 30 June 2024

	Notes	Consolidated 30 June 2024 $	Consolidated 30 June 2023 $
Operating activities			
Receipts from customers		12,022,405	17,244,559
Payments to suppliers and employees		(18,428,566)	(18,476,470)
Interest received		112,330	196,673
Finance costs paid		(22,524)	(109,920)
Income tax (paid) / refund		(53,332)	(250,554)
Net cash flows used in operating activities		**(6,369,687)**	**(1,395,712)**
Investing activities			
Net payments for acquisition of subsidiary		-	(32,395)
Purchase of property, plant and equipment		(356,244)	(65,979)
Payments for intangible assets*		(77,229)	(167,127)
Net cash flows used in investing activities		**(433,473)**	**(265,501)**
Financing activities			
Proceeds from issue of shares		24,002,712	-
Costs of raising capital		(1,060,054)	-
Settlement of loan for Long Term Incentive Plan Shares		5,925	37,917
Dividends paid		-	(442,395)
Repayment of lease liabilities		(298,407)	(141,349)
Net cash flows from/(used in) financing activities		**22,650,176**	**(545,827)**
Net increase/(decrease) in cash and cash equivalents		**15,847,016**	**(2,207,040)**
Cash and cash equivalents			
at beginning of the period		**11,726,424**	**20,296,176**
net foreign exchange differences from translation of cash and cash equivalents		(11,081)	(11,330)
at end of the period		**27,562,359**	**18,077,806**

* Included in payments for intangible assets are amounts incurred on Ultralute $77,229 (2023: $54,086).

The Condensed Consolidated Statement of Cash Flows is to be read in conjunction with the accompanying notes to the Consolidated Interim Financial Report.

Condensed Consolidated Statement of Changes in Equity

For the half year ended 30 June 2024

Consolidated	Contributed Equity $	Other Contributed Equity $	Total Contributed Equity $	Retained Profits / (Accumulated Losses) $	Foreign Currency Translation Reserve $	Employee Equity Benefits Reserve $	Total $
Balance at 1 January 2023	**68,753,968**	**(5,333,158)**	**63,420,810**	**(29,072,834)**	**(1,053,129)**	**3,241,763**	**36,536,610**
Loss for the half year	-	-	-	(2,895,275)	-	-	(2,895,275)
Other comprehensive loss	-	-	-	-	1,243,108	-	1,243,108
Total comprehensive loss for the half year	**-**	**-**	**-**	**(2,895,275)**	**1,243,108**	**-**	**(1,652,167)**
Issue of shares	218,000	-	218,000	-	-	-	218,000
Payment of loan for Long Term Incentive Plan shares	37,917	-	37,917	-	-	-	37,917
Dividends paid	-	-	-	(442,395)	-	-	(442,395)
Cost of share based payments	-	-	-	-	-	233,425	233,425
Total transactions with owners and other transfers	**255,917**	**-**	**255,917**	**(442,395)**	**-**	**233,425**	**46,947**
Balance at 30 June 2023	**69,009,885**	**(5,333,158)**	**63,676,727**	**(32,410,504)**	**189,979**	**3,475,188**	**34,931,390**
Balance at 1 January 2024	**69,114,460**	**(5,333,158)**	**63,781,302**	**(34,658,472)**	**(629,303)**	**3,765,955**	**32,259,482**
Loss for the half year	-	-	-	(7,509,954)	-	-	(7,509,954)
Other comprehensive income	-	-	-	-	(659,238)	-	(659,238)
Total comprehensive loss for the half year	**-**	**-**	**-**	**(7,509,954)**	**(659,238)**	**-**	**(8,169,192)**
Issue of shares	24,238,685	-	24,238,685	-	-	-	24,238,685
Share issue cost (net of tax)	(1,128,425)	-	(1,128,425)	-	-	-	(1,128,425)
Payment of loan for Long Term Incentive Plan shares	198,674	-	198,674	-	-	-	198,674
Dividends paid	-	-	-	-	-	-	-
Cost of share based payments	-	-	-	-	-	149,765	149,765
Total transactions with owners and other transfers	**23,308,934**	**-**	**23,308,934**	**-**	**-**	**149,765**	**23,458,699**
Balance at 30 June 2024	**92,423,394**	**(5,333,158)**	**87,090,236**	**(42,168,426)**	**(1,288,541)**	**3,915,720**	**47,548,989**

The Condensed Consolidated Statement of Changes in Equity is to be read in conjunction with the accompanying notes to the Consolidated Interim Financial Report.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024

1. CORPORATE INFORMATION

The interim financial report of Cyclopharm Limited for the half year ended 30 June 2024 was authorised for issue with a resolution of the directors as of the date of this half year report.

Cyclopharm is a Company limited by shares incorporated and domiciled in Australia. The shares are publicly traded on the Australian Securities Exchange.

The nature of the operations and principal activities of the Group are described in the Directors' Report.

2. BASIS OF PREPARATION

(a) Statement of Compliance

This general purpose condensed consolidated interim financial report for the half-year reporting period ended 30 June 2024 has been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standard *AASB 134 Interim Financial Reporting.* The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Cyclopharm Limited and its controlled entities (referred to as the "Group"). As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this interim financial report be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2023, together with any public announcements made during the following half-year.

(b) Accounting Policies

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements. This condensed consolidated interim financial report has been prepared on a historical cost basis.

(a) Critical Accounting Estimates and Judgments

The critical estimates and judgments are consistent with those applied and disclosed in the December 2023 annual report.

(b) New or Amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ("AASB") that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Set out below is the disaggregation of the Group's revenue from contracts with customers:

	For the period ended 30 June 2024		
	Technegas	Molecular Imaging	Total
Segments	**$**	**$**	**$**
Type of goods or service			
Sales of equipment and consumables - Technegas	6,738,866	-	6,738,866
Sales of equipment and consumables - third party products	4,578,267	-	4,578,267
After sales services - Technegas	722,057	-	722,057
After sales services - third party products	235,464	-	235,464
Total revenue from contracts with customers	**12,274,654**	**-**	**12,274,654**
Geographical markets			
Asia Pacific	2,464,058	-	2,464,058
Europe	8,138,260	-	8,138,260
Canada	1,292,120	-	1,292,120
USA	249,557	-	249,557
Other	130,659	-	130,659
Total revenue from contracts with customers	**12,274,654**	**-**	**12,274,654**
Timing of revenue recognition			
Goods transferred at a point in time	11,377,833	-	11,377,833
Services transferred over time	896,821	-	896,821
Total revenue from contracts with customers	**12,274,654**	**-**	**12,274,654**

	For the period ended 30 June 2023		
	Technegas	Molecular Imaging	Total
Segments	**$**	**$**	**$**
Type of goods or service			
Sales of equipment and consumables - Technegas	7,010,362	-	7,010,362
Sales of equipment and consumables - third party products	6,362,513	-	6,362,513
After sales services - Technegas	638,684	-	638,684
After sales services - third party products	903,424	-	903,424
Total revenue from contracts with customers	**14,914,983**	**-**	**14,914,983**
Geographical markets			
Asia Pacific	5,965,136	-	5,965,136
Europe	7,387,681	-	7,387,681
Canada	1,520,909	-	1,520,909
Other	41,257	-	41,257
Total revenue from contracts with customers	**14,914,983**	**-**	**14,914,983**
Timing of revenue recognition			
Goods transferred at a point in time	14,469,931	-	14,469,931
Services transferred over time	445,052	-	445,052
Total revenue from contracts with customers	**14,914,983**	**-**	**14,914,983**

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

4. SEGMENT REPORTING

		Consolidated	
For the period ended	**Technegas**	**Molecular Imaging**	**Total**
30 June 2024	**$**	**$**	**$**
Revenue			
Sales - Technegas	7,460,923	-	7,460,923
Sales - third-party products	4,813,731	-	4,813,731
Sales to external customers	12,274,654	-	12,274,654
Finance revenue	112,330	-	112,330
Other revenue			
Income from business venture collaboration	-	924,875	924,875
Other revenue	7,520	-	7,520
Total revenue	**12,394,504**	**924,875**	**13,319,379**
Result			
(Loss) / Profit before income tax, depreciation and finance costs	**(7,507,129)**	**923,775**	**(6,583,354)**
Depreciation and amortisation	(767,085)	-	(767,085)
(Loss) / Profit before income tax and finance costs	**(8,274,215)**	**923,775**	**(7,350,440)**
Finance costs	(127,236)	(230)	(127,466)
(Loss) / Profit before income tax	**(8,401,450)**	**923,545**	**(7,477,906)**
Income tax expense	(32,048)	-	(32,048)
Loss for the period	**(8,433,498)**	**923,545**	**(7,509,954)**
Assets and liabilities			
Segment assets	59,608,495	4,483,352	64,091,847
Segment liabilities	16,528,077	14,781	16,542,858

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

4. SEGMENT REPORTING (continued)

		Consolidated	
For the period ended	**Technegas**	**Molecular Imaging**	**Total**
30 June 2023	**$**	**$**	**$**
Revenue			
Sales - Technegas	7,649,046	-	7,649,046
Sales - third-party products	7,265,937	-	7,265,937
Sales to external customers	14,914,983	-	14,914,983
Finance revenue	196,673	-	196,673
Other revenue			
Income from business venture collaboration	-	807,888	807,888
Other revenue	568,074	-	568,074
Total revenue	**15,679,730**	**807,888**	**16,487,618**
Result			
(Loss) / Profit before income tax, depreciation and finance costs	**(2,891,452)**	**807,563**	**(2,083,889)**
Depreciation and amortisation	(465,757)	-	(465,757)
(Loss) / Profit before income tax and finance costs	**(3,357,209)**	**807,563**	**(2,549,646)**
Finance costs	(109,740)	(180)	(109,920)
(Loss) / Profit before income tax	**(3,466,949)**	**807,383**	**(2,659,566)**
Income tax expense	(236,243)	534	(235,709)
Loss for the period	**(3,703,192)**	**807,917**	**(2,895,275)**
Assets and liabilities			
Segment assets	47,537,135	1,772,842	49,309,977
Segment liabilities	14,357,607	20,980	14,378,587

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

5. NET TANGIBLE ASSETS AND LOSS PER SHARE

Net Tangible Assets per share

	Consolidated	
	30 June 2024	31 December 2023
	$	$
Net assets per share	0.43	0.34
Net tangible assets per share	0.38	0.28
	Number	Number
Number of ordinary shares for net assets per share	111,136,850	94,096,326
	30 June 2024	31 December 2023
	$	$
Net assets	47,548,989	32,259,482
Less: intangible assets	(5,758,759)	(5,736,075)
Net tangible assets	41,790,231	26,523,407

The number of ordinary shares is unaffected by Long Term Incentive Performance ('LTIP') shares, as no LTIP shares were issued in the current financial period (2023: 642,500) as set out in Note 15.

Loss per share

	Consolidated	
	30 June 2024	30 June 2023
	$	$
Net loss attributable to equity holders of the parent	(7,509,954)	(2,895,275)
	cents	cents
- basic loss per share from continuing operations	(7.83)	(3.15)
- basic loss per share	(7.83)	(3.15)
- diluted loss per share	(7.83)	(3.15)
	Number	Number
Weighted average number of ordinary shares for basic loss per share	95,861,036	91,792,330
Weighted average number of ordinary shares for diluted loss per share	95,861,036	91,792,330

The weighted average number of ordinary shares for basic loss per share excludes the effects of 100,000 LTIP shares issued on 11 September 2023, 642,500 LTIP shares issued on 23 March 2023 and 3,000 LTIP shares issued on 19 February 2021 (2023: 642,500 LTIP shares issued on 23 March 2023, 267,062 LTIP shares issued on 19 February 2021, 500,000 LTIP shares issued on 4 May 2020 and 250,000 LTIP shares issued on 2 July 2018) as they are contingently returnable.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

6. EXPENSES

	Consolidated	
	30 June 2024	30 June 2023
	$	$
Profit before income tax from continuing operations includes the following specific expenses:		
(a) Cost of materials and manufacturing		
Cost of materials and manufacturing	**5,374,144**	**5,398,963**
(b) Employee benefits expenses		
Salaries and wages	6,948,862	4,874,601
Defined contribution superannuation expense	426,471	364,783
Non-Executive Director fees	156,603	130,562
Share-based payments expense	149,765	233,425
	7,681,701	**5,603,371**
(c) Depreciation and amortisation expenses		
Depreciation of land and buildings	5,111	5,146
Depreciation of plant and equipment	105,728	108,601
Depreciation of leasehold improvements	139,790	138,864
Depreciation of leased assets	484,053	141,349
Amortisation of intangibles	32,403	71,797
	767,085	**465,757**
(d) Research & development expenses		
FDA expenses	-	2,966,495
Pilot Clinical Trial expenses	168,515	-
Research expenses	40,954	116,342
	209,469	**3,082,837**
(e) Administration expenses		
Legal and professional costs	861,578	770,187
Office and facility costs	1,006,015	785,885
Travel and motor vehicle costs	1,119,881	687,179
Consulting fees	493,555	434,163
Regulatory costs	483,306	343,059
ASX and share registry costs	89,527	89,500
Other administration costs	995,545	184,354
	5,049,407	**3,294,327**
(f) Finance costs		
Bank and other finance charges	22,525	13,519
Interest on leased assets	104,941	96,401
	127,466	**109,920**

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

7. TRADE AND OTHER RECEIVABLES

		CONSOLIDATED	
		30 June 2024	31 December 2023
	Notes	$	$
Current			
Trade receivables, third parties		4,930,081	5,844,950
less: Allowance for expected credit losses		(142,897)	(100,317)
	(i)	4,787,184	5,744,633
Other receivables	(ii)	2,030,888	648,046
Deposits to suppliers		1,329,230	1,502,374
Total Current trade and other receivables		**8,147,302**	**7,895,053**
Total trade and other receivables		**8,147,302**	**7,895,053**

(i) Trade receivables are non-interest bearing and generally on 30 and 60-day terms.

(ii) Other receivables are non-interest bearing and have repayment terms between 30 and 90 days.

The ageing of Cyclopharm's trade receivables and allowance for impairment loss are as follows:

	Trade receivables		Allowance for expected credit losses		Trade receivables net of allowance for impairment losses	
	30 June 2024	31 December 2023	30 June 2024	31 December 2023	30 June 2024	31 December 2023
	$	$	$	$	$	$
Trade receivables						
0 - 30 days	3,970,969	3,715,962	-	-	3,970,969	3,715,962
31 - 60 days	532,471	369,596	-	-	532,471	369,596
61 - 90 days	105,476	189,768	-	-	105,476	189,768
over 90 days	321,165	1,569,624	(142,897)	(100,317)	178,268	1,469,307
	4,930,081	**5,844,950**	**(142,897)**	**(100,317)**	**4,787,184**	**5,744,633**
Other receivables	2,030,888	648,046	-	-	2,030,888	648,046
Deposits to suppliers	1,329,230	1,502,374	-	-	1,329,230	1,502,374
Trade and other receivables	**8,290,199**	**7,995,370**	**(142,897)**	**(100,317)**	**8,147,302**	**7,895,053**

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

8. INVENTORIES

	CONSOLIDATED	
	30 June 2024	31 December 2023
	$	$
Current		
Raw materials at cost	8,429,522	8,287,237
Finished goods	2,032,625	1,899,508
Provision for obsolescence	(70,069)	(64,729)
Total current inventory	**10,392,078**	**10,122,016**
Non-current		
Finished goods	-	33,836
Total non-current inventory	**-**	**33,836**
Total inventory	**10,392,078**	**10,155,852**

9. RIGHT-OF-USE ASSETS

	Consolidated	
	30 June 2024	31 December 2023
	$	$
Land and buildings - right-of-use	6,320,863	5,217,008
Less: Accumulated depreciation	(2,217,489)	(2,033,633)
	4,103,374	**3,183,375**
Motor vehicles - right-of-use	614,156	158,993
Less: Accumulated depreciation	(388,212)	(129,053)
	225,944	**29,940**
Total right-of-use assets	**4,329,318**	**3,213,315**

The Group leases land and buildings for its offices, manufacturing facilities and warehouse under agreements of between two to ten years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are negotiated. The Group also leases motor vehicles under agreements of three to four years.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received.

The right-of-use asset is amortised on a straight-line basis over its useful life.

The Group has elected not to recognise a right-of-use asset and a corresponding lease liability for leases with a term of less than 12 months or for leases of low-value assets. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

10. INTANGIBLE ASSETS

CONSOLIDATED	Intellectual property $	Goodwill on consolidation* $	Licences $	Technegas Development $	Target $	Ultralute $	Total $
Balance at							
1 January 2024	161,176	903,513	795,117	788,588	27,419	3,060,262	**5,736,075**
Additions during the period	-	-	-	-	-	77,229	77,229
Disposals during the period	-	-	-	-	-	-	-
Foreign exchange translation	-	(10,052)	(12,090)	-	-	-	(22,142)
Amortisation for the period	(13,536)	-	(18,867)	-	-	-	(32,403)
Balance at							
30 June 2024	**147,640**	**893,461**	**764,160**	**788,588**	**27,419**	**3,137,491**	**5,758,759**
30 June 2024							
Non-Current	147,640	893,461	764,160	788,588	27,419	3,137,491	5,758,759
Total	**147,640**	**893,461**	**764,160**	**788,588**	**27,419**	**3,137,491**	**5,758,759**
31 December 2023							
Non-Current	161,176	903,513	795,117	788,588	27,419	3,060,262	5,736,075
Total	**161,176**	**903,513**	**795,117**	**788,588**	**27,419**	**3,060,262**	**5,736,075**

* Goodwill on consolidation arising upon the acquisition of Cyclomedica Benelux bvba on 1 October 2017, Cyclomedica Nordic AB on 1 May 2018 and Dupharma ApS on 1 April 2023.

11. TRADE AND OTHER PAYABLES

		Consolidated	
	Notes	30 June 2024 $	31 December 2023 $
Current			
Trade payables, third parties	(i)	3,797,259	3,147,364
Other payables and accruals	(ii)	2,280,366	2,437,010
Deposits from customers		1,931,975	1,357,538
Total current trade and other payables		**8,009,600**	**6,941,912**
Total trade and other payables		**8,009,600**	**6,941,912**

(i) Trade payables are non-interest bearing and are normally settled on 30-60 day terms.

(ii) Other payables and accruals are non-interest bearing and have an average term of four months.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

12. LEASE LIABILITIES

	Consolidated	
	30 June 2024	31 December 2023
	$	$
Current		
Lease liabilities	916,317	214,465
Lease liabilities (current)	**916,317**	**214,465**
Non-current		
Lease liabilities	4,654,826	4,012,832
Lease liabilities (non-current)	**4,654,826**	**4,012,832**
Total financial liabilities	**5,571,143**	**4,227,297**
Total facilities	5,571,143	4,227,297
Facilities used at reporting date	(5,571,143)	(4,227,297)
Facilities unused at reporting date	**-**	**-**

At the date of commencement of a lease, a lease liability is recognised. The liability is initially measured at the present value of future lease payments, discounted using the Group's incremental borrowing rate.

Over the life of the lease, the lease liability will be increased by interest costs and will be reduced as lease payments are made.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

13. PROVISIONS

	Consolidated	
	Employee Entitlements	Total
	$	$
Balance at 1 January 2024	**1,546,591**	**1,546,591**
Arising during the period	981,791	981,791
Utilised	(532,351)	(532,351)
Foreign currency movement	(4,433)	(4,433)
Balance at 30 June 2024	**1,991,598**	**1,991,598**
30 June 2024		
Current	1,747,247	1,747,247
Non-Current	244,351	244,351
Total	**1,991,598**	**1,991,598**
Number of employees		
Number of employees at period end	98	
31 December 2023		
Current	1,475,407	1,475,407
Non-Current	71,184	71,184
Total	**1,546,591**	**1,546,591**
Number of employees		
Number of employees at year end	87	

14. DEFERRED INCOME

A portion of the Research & Development Grant refund received has been recognised as deferred income liabilities and will be amortised over the same period as the amortisation of the related intangible development asset.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

15. CONTRIBUTED EQUITY

		Consolidated			
		30 June 2024	30 June 2023	30 June 2024	30 June 2023
	Notes	Number	Number	$	$
(a) Contributed equity					
Issued and paid up capital					
Ordinary shares		111,136,850	93,796,326	92,423,394	69,009,885
Other contributed equity		-	-	(5,333,158)	(5,333,158)
Total issued and paid up capital		**111,136,850**	**93,796,326**	**87,090,236**	**63,676,727**
Ordinary shares					
Issued and paid up capital					
Balance at the beginning of the period		94,096,326	93,053,826	69,114,460	68,753,968
Issue of Long Term Incentive Plan shares	(i)	-	642,500	-	-
Payment of loan for Long Term Incentive Plan shares	(ii)	-	-	198,674	37,917
Issue of shares	(iii)	-	100,000	-	218,000
Issue of shares	(iv)	16,903,181	-	24,002,712	-
Issue of shares	(v)	137,343	-	235,973	-
Share issue cost (net of tax)		-	-	(1,128,425)	-
Balance at the end of the period		**111,136,850**	**93,796,326**	**92,423,394**	**69,009,885**
(b) Other contributed equity					
Balance at the beginning of the period		-	-	(5,333,158)	(5,333,158)
Balance at end of period		**-**	**-**	**(5,333,158)**	**(5,333,158)**
Total contributed equity				**87,090,236**	**63,676,727**

Ordinary shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder to one vote, either in person or by proxy, at a meeting of the Company.

(i) On 23 March 2023, 642,500 LTIP shares were issued at an exercise price of $1.82 per share under the non-recourse loan payment plan,
(ii) Proceeds from settlement of loans to acquire LTIP shares,
(iii) On 14 April 2023, 100,000 ordinary shares were issued at a deemed price of $2.18 per share as part consideration to acquire 100% of the shares in Dupharma ApS. These shares were subject to voluntary escrow until 31 March 2025 and had no dividend or voting rights until 1 April 2025. These shares were released from voluntary escrow on 1 April 2024.
(iv) On 30 May 2024, 11,971,832 ordinary shares were issued at a price of $1.42 per new share in connection with an institutional share placement. On 4 June 2024 a further 2,112,676 ordinary shares were issued at a price of $1.42 per new share in connection with the same institutional share placement. On 28 June 2024, 2,818,673 ordinary shares were issued at a price of $1.42 per new share in connection with a share purchase plan to eligible shareholders.
(v) On 5 April 2024, 93,443 ordinary shares were issued at a price of $1.83 per new share as consideration for an employee performance bonus. On 28 June 2024, 43,900 ordinary shares were issued at a price of $1.48 as consideration for an employee performance bonus.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024
Continued

15. CONTRIBUTED EQUITY (continued)

Dividends

There were no dividends paid during the current financial period (2023: unfranked final dividend of 0.5 cents per share in respect of the financial year ended 31 December 2022). In the previous corresponding financial period, the Directors had declared an unfranked interim dividend of 0.5 cents per share which had not been recognised in those condensed consolidated financial statements as it was declared subsequent to 30 June 2023.

	Consolidated			
	30 June 2024	30 June 2023	30 June 2024	30 June 2023
	Cents per share	Cents per share	$	$
Fully paid ordinary shares				
Final dividend for the financial year				
- No franking credits attached	-	0.5	-	(442,395)
- Fully franked at 30% corporate tax rate	-	-	-	-
	-	**0.5**	**-**	**(442,395)**

16. COMMITMENTS AND CONTINGENCIES

(a) Capital commitments

Cyclopharm has entered into agreements to fund research projects with unrelated institutions. The commitments for these projects total $1,222,533 (2023: $267,166) and will be expensed when incurred. Payments will be made based on the achievement of certain milestones.

There were no other capital commitments as at the date of this report.

(b) Contingent liabilities

In December 2019, a business venture collaboration agreement combined CycloPet Pty Ltd and Pettech Solutions Limited's cyclotron facilities under a single operating enterprise known as Cyclotek NSW Pty Limited (Cyclotek NSW). Cyclopharm and Cyclotek NSW have entered into a sub-lease agreement as tenants in common whereby Cyclotek NSW is solely responsible for the tenant's obligations except for make good obligations until such time as it exercises the right to transfer its interest as tenant in common to Cyclopharm. Being a tenant in common, Cyclopharm's contingent liabilities as at 30 June 2024 amounts to $3,124,657 (2023: $3,286,657) if Cyclotek NSW is unable to fulfil its obligations as tenant. The amount comprises payments under a sub-lease agreement commencing 1 January 2020 until the expiry of two options to renew expiring on 31 December 2039 with a rent-free period until 31 December 2022.

There were no other contingent liabilities as at the date of this report.

17. SIGNIFICANT RELATED PARTY TRANSACTIONS

The condensed consolidated financial statements include the financial statements of Cyclopharm and its subsidiaries. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company have been eliminated on consolidation and are not disclosed in this note. There were no transactions entered into with related parties for the half-year period.

Ultimate parent entity

Cyclopharm Limited is the ultimate parent entity in the wholly owned group.

Notes to Consolidated Interim Financial Report

For the half year ended 30 June 2024

Continued

18. EVENTS AFTER THE BALANCE SHEET DATE

No matters or circumstances have arisen since the end of the financial period, not otherwise dealt with in the financial report, which significantly affected or may significantly affect the operations of the economic entity, the results of those operations, or the state of affairs of the economic entity in future financial periods.

`

Directors' Declaration

In the opinion of the directors of Cyclopharm Limited:

1. (a) The financial statements and notes of the consolidated entity are in accordance with the Corporations Act 2001, including:

    (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2024 and of its performance for the half-year ended on that date; and

    (ii) complying with Accounting Standard *AASB 134 Interim Financial Reporting*, Corporations Regulations 2001 and other mandatory professional reporting requirements.

    (b) There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to section 303(5) of the Corporations Act 2001:

James McBrayer
Managing Director & CEO

Sydney, 27 August 2024

Independent Auditor's Review Report

Nexia Sydney Audit Pty Ltd
Level 22, 2 Market Street
Sydney NSW 2000
PO Box Q776
QVB NSW 1230
E: info@nexiasydney.com.au
P: +61 2 9251 4600
F: +61 2 9251 7138

nexia.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF CYCLOPHARM LIMITED

Report on the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Cyclopharm Limited (the Company and its subsidiaries ("the Group")), which comprises the condensed consolidated statement of financial position as at 30 June 2024, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

i) giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the half-year ended on that date; and

ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the Directors for the Financial Report

The directors of the Group are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Nexia Australia

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 30 June 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Nexia

Nexia Sydney Audit Pty Ltd

Stephen Fisher
Director

Sydney, 27 August 2024

General Information

Directors

David Heaney
Non-Executive Chairman

James McBrayer
Managing Director & CEO

Dianne Angus
Non-Executive Director

Kevin Barrow
Non-Executive Director

Professor Greg King
Non-Executive Director

John Wigglesworth
Non-Executive Director

Company Secretary
James McBrayer

Registered Office
Cyclopharm Limited
Unit 4, 1 The Crescent
Kingsgrove NSW 2208
Australia
T: 02 9541 0411
F: 02 9543 0960
E: corporate@cyclopharm.com.au

Cyclomedica Australia Pty Limited
Unit 4, 1 The Crescent
Kingsgrove NSW 2208
Australia
T: 02 9541 0411
F: 02 9543 0960

CycloPET Pty Limited
Unit 4, 1 The Crescent
Kingsgrove NSW 2208
Australia

Cyclomedica Canada Limited
Suite 23, 35 Main St N.
Waterdown,
Ontario L0R 2H0
Canada

Cyclomedica Germany GMBH
Marie-Curie Strasse 8
51377 Leverkusen
Germany

Cyclomedica Europe Ltd
Unit A5,
Calmount Business Park
Ballymount
Dublin 12, D12 AX06
Ireland

Cyclomedica Nordic AB
Gustavslundsvagen 145
SE-16751 Bromma,
Sweden

Cyclomedica Benelux bvba
Rue des Francs 79
Etterbeek 1040,
Belgium

Cyclomedica UK Ltd
Moore 6th Floor,
Whitefriars,
Lewins Mead,
Bristol
United Kingdom BS1 2NT

Dupharma ApS
Kirstinehøj 17,
2770 Kastrup,
Denmark

Cyclomedica USA LLC
5126 S Royal Atlanta Drive
Tucker, GA USA 30084-3052

Auditors
Nexia Sydney Audit Pty Ltd
Level 22
2 Market Street
Sydney NSW 2000
Australia

Share Registry
Automic Pty Limited, trading as Automic (AIC 22031)
Level 5
126 Philip Street
Sydney NSW 2000
Australia
T: 1300 288 664 / 02 9698 5414
F: 02 8583 3040
E: hello@automic.com.au

Bankers
National Australia Bank
Level 21, 255 George Street
Sydney NSW 2000
Australia

Solicitors
Thomson Geer Lawyers
One Eagle – Waterfront Brisbane
Level 28, 1 Eagle Street
Brisbane QLD 4001
Australia

Securities Exchange Listing
The ordinary shares of Cyclopharm Limited are listed on the Australian Securities Exchange Ltd (ASX:CYC)